231 related articles for article (PubMed ID: 23233566)
1. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
Ghia P
Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
[TBL] [Abstract][Full Text] [Related]
2. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
5. [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
Plander M; Skrapits J; Bozsó T; Szendrei T; Iványi JL
Orv Hetil; 2012 Oct; 153(41):1622-8. PubMed ID: 23045312
[TBL] [Abstract][Full Text] [Related]
6. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
7. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
9. Assessing minimal residual disease in chronic lymphocytic leukemia.
Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
[TBL] [Abstract][Full Text] [Related]
10. Is MRD eradication a desirable goal in CLL?
Moreno C; Ritgen M; Rawstron A
Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
[TBL] [Abstract][Full Text] [Related]
11. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
13. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
14. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Thompson PA; Wierda WG
Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
Nabhan C; Coutré S; Hillmen P
Br J Haematol; 2007 Feb; 136(3):379-92. PubMed ID: 17129223
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods.
Böttcher S
Methods Mol Biol; 2019; 1881():211-238. PubMed ID: 30350209
[TBL] [Abstract][Full Text] [Related]
17. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
Böttcher S; Stilgenbauer S; Busch R; Brüggemann M; Raff T; Pott C; Fischer K; Fingerle-Rowson G; Döhner H; Hallek M; Kneba M; Ritgen M
Leukemia; 2009 Nov; 23(11):2007-17. PubMed ID: 19641522
[TBL] [Abstract][Full Text] [Related]
18. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
19. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
Ysebaert L; Gross E; Kühlein E; Blanc A; Corre J; Fournié JJ; Laurent G; Quillet-Mary A
Leukemia; 2010 Jul; 24(7):1310-6. PubMed ID: 20463751
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease assessment in chronic lymphocytic leukaemia.
Sayala HA; Rawstron AC; Hillmen P
Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]